Selvita_Development-Strategy-2022-2025.pdf

March 31, 2022
DEVELOPMENT
STRATEGY 2022-25

Disclaimer
2
This presentation ("Presentation") has been prepared by Selvita S.A. with its registered office in Cracow (the "Company") and is intended for informational
purposes only. Its purpose is to present selected data on Selvita S.A. Group and its development prospects. The information contained in this Presentation
that is not directly derived from periodic reports published by Selvita S.A. has not been subject to independent verification; therefore, there is no guarantee
that it is complete and fully reflects the actual situation.
The presentation should not be considered as investment advice, a recommendation, an offer to buy or sell any securities or financial instruments or to
participate in any trading venture.
This Presentation contains forward-looking statements. Forward-looking statements contained in this Presentation, including, but not limited to,
statements regarding the Company's earnings and development, are based on a number of assumptions, expectations and projections that are subject to
risks of uncertainty and may change as a result of external and internal factors and should not be relied upon as binding forecasts. Neither the Company
nor any persons acting on its behalf, in particular the members of the Management Board, the Company's advisors or any other persons, give any
assurance that the forward-looking statements will be fulfilled, and in particular they do not guarantee that future results or events will be consistent with
these statements, or that the Company's future results will not differ materially from the forecasts. Accordingly, the Company expressly declares that
forward-looking statements are not guarantees of future performance and its actual financial condition, business strategy, plans and objectives of
management for future operations may differ materially from those expressed or implied by such statements in this Presentation. This Presentation does
not constitute the publication of any projections by the Company.
The information contained herein is current only as of the date hereof and is subject to material change. The Presentation will not be amended, updated or
modified to reflect any changes occurring after that date, unless required by applicable law.
Selvita S.A. shall not be liable for the effects of decisions made after reading the Presentation. The only reliable sources of information on the financial
performance of the Company and the Group are current and periodic reports published by Selvita S.A. as part of its legal obligations to provide
information.
This Presentation is not intended for distribution to, or in, any state where the public dissemination of the information contained in this Presentation may
be restrictions or be prohibited by law.

Who are we?
DRUG DISCOVERY
Selvita is an integrated service company
(Contract Research Organisation) providing
multidisciplinary support in resolving the unique
challenges of research within area of:
REGULATORY STUDIES

4
Selvita Group at a glance in 2022
5
continents
40+
countries
~750
customers
4000+
completed projects
Including 7/10largest, global biotech
and pharma companies
6 locations
in PL, HR, UK and US
12 000 m²
research space
900+
employees
300+
MLN EUR market cap
46%
revenue CAGR in years 2014-2021

Our competitiveness on the CRO market
5
Experienced scientific team
Technology and research infrastructure
Efficient communication and corporate culture
Located in the heart of Europe
Price competitive

0
10
20
30
40
50
60
70
IPO on Warsaw Stock
Exchange
New sales offices in the USA:
Boston and San Francisco
and in the UK: Cambridge
New laboratory
in Poznan
[EURm]
Revenues
Corporate split into:
Ryvu Therapeutics and Selvita
2014 2015 2016 2017 2018 2019 2020
Acquisition of
SPO on WSE
EUR 20.4 m raised
2021
founded
Consistent and continued development
Selvita ahead of time
in realization of
Development
Strategy for
2020 - 2023
Revenues ~EUR70m,
stable EBITDA margin
6
Market cap >EUR 230m
Growth through
acquisitions
69.3m

Selvita compared to other
CROs

8
Growing position among peers
Revenue growth - Selvita vs peers (EURm)
1Excl. Sygnature,& Symeres with data for 2020
• Selvita's revenue growth CAGR over 10 years was 45%
• Thanks to the dynamic increase in revenues, Selvita has achieved the scale of medium-sized entities, such as: Symeres or
Sygature Discovery
• The company's goal is further growth, which will bring it closer to the largest entities in the industry
0
10
20
30
40
50
60
70
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Selvita Sygnature Symeres
b.d.
Position compared to market leaders – data for 20211 (EURm)
53 59 69
119
560
Sygnature Symeres Selvita Nuvisan Evotec Pharmaron Wuxi App
Charles
River Lab
982
3,161 3,174
8

High operational efficiency
Sales and EBITDA per FTE (data for 20211, EUR thousand)
EBITDA margin of key players (in %)
• Selvita Group systematically increases the profitability of the provided services. The EBITDA margin for 2021 was at 27%.
• Along with expanding the scope of services and acquiring high-margin projects, the Group will increase the level of revenues
and EBITDA per employee.
1Data for Sygnature Discovery, Symeres is for 2020, due to lack of information for 2021
92,7 96,0
132,7 135,6
146,3
164,6
25,0 32,0 38,4 30,8 33,1
46,7
0
50
100
150
200
Selvita Wuxi App Sygnature Symeres Evotec Charles River
Lab.
Przychody/FTE EBITDA/FTE
Sales/FTE EBITDA/FTE
-10%
0%
10%
20%
30%
40%
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021F
Selvita Sygnature Symeres
Evotec Charles River Lab Wuxi App
9

10
Transition to a new phase of development
Source: Markets&Markets; Drug Discovery Services Market Global Forecast to 2026, January 2022
SCOPE OF OFFER
MARKET
SHARE
/
RANK
PARTICIPANT PERVASIVE PLAYER
EMERGING LEADER STAR
Currently, Selvita is one of the
medium-sized CRO companies
that is distinguished by its
dynamics of development
Selvita's goal for the upcoming
years is to move its position on
the value matrix towards the
perception as a leader with a
comprehensive services offer

Development Strategy
2022 - 2025

24.5
31.8
69.3
2019 2020 2021
Przychody GK Selvita w latach 2019-2021 [PLNm]
Accelerated implementation of the Strategy announced in 2020
12
Goals for 2020–2023:
Revenues at the level of app.
EUR 70m with stable EBITDA margin
Market cap above EUR 230m
Growth through acquisitions
CAGR
74%
Selvita’s market value exceeds EUR 300m
Acquisition of Fidelta
(~40% of total Group revenues)
Group revenues at the level of EUR 69.3m
for 2021 with increasing EBITDA margin
Execution as of the end of 2021:
3x
Selvita Group revenues in 2019-2021 [EUR m]
12

Integration of Fidelta and preparing the Group
for further development – changes at the Board
ADRIJANA VINTER, PH.D.
GLOBAL HEAD OF DRUG DISCOVERY
Sales teams integration
Integration of drug discovery area
Strengthening the operational area
Maximizing synergies, further development based on
high-value services, implementation of new research
competences
Focus on the effective sale of the entire offer,
maximum use of the potential to further build
a position on the market
Creation of the Operations and Investment Support
department responsible for the development and
optimization of processes and the implementation
of the latest IT technologies
MIŁOSZ GRUCA, PH.D.
CHIEF COMMERCIAL OFFICER, EVP
MIROSŁAWA ZYDROŃ, PH.D.
CHIEF OPERATING OFFICER
13

14
Strategic Goals 2022-2025
Focus on services with high customer value
• Specialization in selected therapeutic areas
• Unique competences
Strong presence in the largest markets in the US and UK
Comprehensive offer in the area of drug discovery and development
• Supplementing the drug discovery offer
• Building the drug development segment
Selvita as a leading global preclinical CRO providing services in
the field of drug discovery and development, accelerating access to new
therapies for patients

15
Strategic Goals 2022 - 2025
3x growth with high profitability
34% CAGR of
revenues
Revenue
>EUR 200m
High
EBITDA
margin

Acquisitions
• Additional EUR 30-50m of revenues thanks to acquisitions.
Financing up to EUR 110m from own resources and available debt
• Interest in companies:
o in drug development area (CDMOs)
o supplementing competencies in the area of drug discovery
o located in Europe and North America
o from new technological areas
16
Rozwój
organiczny
• Continued dynamic organic growth, CAGR >23%
• Planned increase in employment >70%
• Construction of the second laboratory facility in Krakow
• Expansion of the leased laboratory space in Zagreb and Poznan
Revenue growth strategy
Organic Growth

17
Selvita 2025
• Around 1,600 scientists and experts in several
locations:
o Krakow, Zagreb, Poznan
o Another location in Europe (acquisition)
o Project Teams in Cambridge and Boston
o Laboratories in North America (acquisitions or organically)
• Strong presence and brand recognition in the US
and UK
• A comprehensive range of drug discovery and
drug development services
Selvita as a global
preclinical CRO
EUR 200m in revenues, high EBITDA

19
Dynamic growth of the market is favorable for CROs
• The global drug discovery market is expected to almost double its size in 2021-2026
• The leading market segments by therapeutic area are: oncology, infectious diseases and neurological disorders
• The leading therapeutic segments match the areas of specialization for both Fidelta and Selvita
2019 2020 2021 2026 P
Ameryka Północna Europa Azja i Pacyfik Ameryka Łacińska Bliski Wschód i Afryka
Value of the global drug discovery market (USD bn)
14.4%
CAGR
13.5%
CAGR
15.9%
CAGR
12.6%
CAGR
9.8%
CAGR
10.1
12.5
16.1
31.4
North America Europe Asia & Pacific Latin America Middle East & Africa

Significant presence on major markets
20
47.1%
27.8%
12.2%
8.7%
4.2%
EU Countries
USA
UK
Switzerland
Other
EURm Split of commercial revenues per market Revenue structure (2021)
• The international profile of the Company with a dominant share of clients from the EU, the US, and the UK
• Dynamic growth of revenues in the US (95% y/y) and UK (171% y/y), accomplished thanks to the acquisition of Fidelta and
organic growth of Selvita and Ardigen
• Significant growth potential, especially in the US, where Selvita’s market share still accounts for a small percentage of the
market potential available to mid-sized CROs
14.3
9.7
3.1 1.5 1.5
32.0
18.9
8.3
5.9
2.8
EU Countries US UK Switzerland Other
2020 2021

Selvita Group's Market Strategy
21
Selvita closer to the client
• New locations on key markets (US, UK) thanks to acquisitions or organic growth
• Building the relationship with the client at every stage of the project
• Strengthening foreign BD teams
Leveraging over 50 years of cummulative experience in drug
discovery (Selvita + Fidelta)
• Strong brand after Selvita and Fidelta integration – supplemented with potential
acquisitions
• Comprehensive solutions in the field of preclinical drug discovery
Offer tailored to the needs of customers on the key markets
• The critical distinguishing feature of the competitive market (as in the US) is the
offer tailored to the demanding customers
• Competing with competencies and approach to the client, not with the price
• Biology services, as the main growth factor for integrated projects
Strong
brand
Closer to
the client
50 years
of experience
Selvita as an experienced and fully integrated service
provider in the field of preclinical drug development

22
Full integration under the Selvita brand
Business goal:
To build comprehensive research capabilities bridging the gap between early drug
discovery and clinical research.
• New development opportunities – building a single, strong brand that
operates globally
• Efficient and effective sale of services offer covering the scope provided
both by labs in Poland and Croatia, requires integration under one brand
• Integrating sales activities, as a step to strengthen the position on the market
– joint sales offer, promotion of one brand at industry events - facilitates
communication with customers
Operating under one brand is an important step in Selvita's evolution
As of March 31 this year, Fidelta will operate under the Selvita brand while
remaining a subsidiary company.

23
Record-breaking financing in biotech
Acquired capital and number of IPOs on Western Markets [USD bn]
0.5
1.1
0.7
1.4
2.5
2017 2018 2019 2020 2021
Funds obtained from VC market in UK [GBP bn]
• Record-breaking financing of biotech companies is a very good prognostic indicator for the CROs
• The US is by far the largest market (86 IPOs in 2021)
• In Europe the UK market accounts for approx. 40% of the total capital raised in 2021
• The capital raised in the US begins to translate into an increase in the demand for CRO services in Europe as well
7.2
4.9
12.7
14.2
68
55
76
98
0
20
40
60
80
100
120
2
4
6
8
10
12
14
16
2018 2019 2020 2021
Pozyskany kapitał Liczba IPO
Source: UK BioIndustry Association; UK biotech financing in 2021
Source: https://www.evaluate.com/vantage/articles/insights/venture-financing/2021-it-paid-stay-private-when-chips-were-down
Capital acquired # of IPOs

Development in key markets: United States
• In the next 2-3 years, the US market should dominate in terms
of revenues generated by Selvita
• The main factors determining the success of CRO companies
are: access to innovative technologies, an experienced research
team, and a comprehensive offer
• The increase in recognition of the Selvita brand on the US
market and the acquisition of Fidelta translate into a significant
increase in revenues
• Tensions between the US and China lead to increased
geographical diversification of research the partners of the US
biotechnology companies
24
Commercial revenues in US [EURm]
5.5
9.7
14.2
4.6
2019 2020 2021
Selvita Fidelta
CAGR
90%
United States – a huge growth potential,
innovative technologies

2.4
3.1
4.7
3.6
2019 2020 2021
Selvita Fidelta
Development in key markets: Great Britain
• The golden age of the biotechnology sector - well-funded
biotechnology companies with high demand for the
outsourcing of research projects
• In 2021 alone, UK companies raised around £4.5 billion
(public and private investors)
• One of the key markets when it comes to the
development of Selvita's offer in the area of integrated
projects
• The highest dynamics of revenue growth in Selvita Group
25
CAGR
116%
Commercial revenues in UK (EURm)
Great Britain – great financing,
integrated projects

Building a position in key markets
Development of research teams in foreign markets
26
• Creating a local interface for clients responsible for direct
contact with research teams in Poland
• Coordination of IDD projects - bringing teams carrying out
research tasks in Poland closer to clients in key markets
• Initiating the process of creating research teams in the US
and UK - an additional level of consulting used in sales
processes
• In times of high geopolitical instability, this strategy will enable
continuous recruitment of highly qualified specialists from the
local scientific community
One of the elements of Selvita's sales strategy will be the development of research teams
operating in key markets such as the United Kingdom and the United States

M&A drivers and market trends in the preclinical CRO space
• Strong tendency to outsource in the biotechnology
and pharmaceutical sectors. The growing share of
outsourcing in the drug discovery process and insufficient
internal expertise drive activity in the area of mergers
and acquisitions
• Consolidation of the market. CROs seek to add scale,
broaden geographical presence and achieve synergies.
Increased competition for niche CRO assets
• Increasing uptake of technology. Use of AI and machine
learning in drug discovery as a key differentiator
• The one-stop-shop approach, i.e. comprehensive CRO
and CDMO activities within one organization
• Extending the offer with new therapeutic areas or
modalities using M&A
• High transaction activity in the industry in recent years.
A significant increase in the activity of private equity funds 62
79
92
71
132
2017 2018 2019 2020 2021
Number of M&A transactions on CRO market is increasing
Global CRO Market Penetration Rate, %
Source: Results Healthcare; CRO sector M&A drivers and market trends, Q1 2022
33.7
34.8
36.3 36.5
37.7
39.5
41.7
44.2
46.8
49.3
2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
28

Horizontal Expansion
Strengthening portfolio,
scaling existing
capabilities
/Bioanalytical studies, GLP Tox studies,
DMPK, CNS expertise/
Geographic Expansion
US and UK as the main
markets for Selvita
Technology Expansion
Opportunistic acquisition.
A gateway into new
modalities
Vertical Expansion
Combining CRO with CDMO
activity. Selvita as an end-to-
end provider
/Pre-formulation capabilities, clinical
batches manufacturing, GMP scale-up/
Selvita development through M&A
TARGET CRITERIA: Small and medium companies
with a good track record that may require
reorganization or have not built extended sales
network to release their full potential
QUANTITATIVE CRITERIA: EUR 5-35m revenues
NUMBER OF EMPLOYEES: 30-250
Total revenues that Selvita plans
to "acquire" thanks to M&A: EUR 30-50m
29

Financing M&A Strategy
• Approximately EUR110 million (cash + debt) to finance
acquisitions
• Healthy balance sheet allows Selvita to primarily finance
acquisitions through debt
• Gross leverage ratio to be kept below 3x
• Possibility to finance acquisitions of bigger-sized players
through issue/swap of shares
• Strong demand resulted in an increase in the valuations of
CRO companies. The median P / S ratio of public CRO
deals over the past 5 years was 3.3x *, while current EV /
EBITDA valuations are around 20x
• Targets that are too small for the bigger players can be
potentially acquired at lower multiples
• Selvita plans to acquire companies whose multipliers will
be lower than Selvita's
EURm Debt Available cash Net Debt
Selvita Capital Group 39.0 21.2 17.8
EBITDA 18.6
Net debt/EBITDA 0,97x
Valuations of CRO companies are at record high
EBITDA
30
* Source: MergerMarket Source: Results Healthcare; CRO sector M&A drivers and market trends, Q1 2022

Drug discovery
& drug development

4.8
4.1
2.4 2.0
1.2 1.6
9.4 8.7
4.5 4.1
2.0 2.7
Oncology Infectious & Immune
System Diseases
Neurology Digestive System
Diseases
Cadriovascular
Diseases
Other Therapeutic
Areas
2021 2026
32
Drug discovery services market
• The global drug discovery services market forecast for
2021-2026:
• projected to reach USD 31.4 billion by 2026,
increasing from USD 16.1 billion in 2021
• CAGR of 14.3%
Drug Discovery services growth dynamics by Therapeutic Area (USDbn)
13,5%
CAGR
by Therapeutic Area
14.5%
CAGR
16.4%
CAGR
13.5%
CAGR
15.2%
CAGR
11.0%
CAGR
10.3%
CAGR
• Oncology segment
• accounts for the largest share of the therapeutic
area segment
• Neurosciences
• the third biggest therapeutic area

33
Drug discovery services market
• Hit-to-lead identification segment
• the largest share of the drug discovery services
market in 2020
• plays vital role in the drug discovery and is the
most revenue-generating process
• characterized by the highest growth dynamics
• Lead optimization segment
• is the second biggest by revenue
• records double-digit growth increases
Drug Discovery services growth dynamics by Process (USDbn)
3.2
0.9
6.9
4.1
1.0
5.4
1.6
14.7
7.6
2.0
Target
Selection
Target
Validation
Hit-to-Lead
Identification
Lead
Optimization
Candidate
Validation
2021 2026
11.3%
CAGR
12.4%
CAGR
16.3%
CAGR
13.3%
CAGR
14.8%
CAGR
by process

34
Leveraging history with dynamic growth and broad market access to create the future
Long term experience in DD demonstrated by clinical candidates
Translational approach to Drug Discovery projects
Following marketing trends
Passion for discovering new drugs
Dynamic growth
Basis of strategy

35
Strategy for 2022-2025
By offering deep scientific knowledge and focusing on the disease and the patient,
we will help clients to accelerate their projects towards the clinic
Offering comprehensive drug discovery and drug development services by
• Filling the gaps in drug discovery offer
• Building drug development segment
Prime research solutions – focus on competence centers and specialized capabilities
• Further development of established therapeutic areas
• Expanding Oncology and Neurosciences
• Strengthening position on the market as an integrated drug discovery services provider
• AI and structural biology support for drug discovery services
• Drug Development services for biopharmaceuticals

Compounds library
including fragments
In vivo Oncology
In vivo Neurosciences
In vitro tox studies
GLP Tox
Small scale GMP production capabilities
Target
deconvolution
AI/ML tools/services – in house and in cooperation with Ardigen
Scale-up, optimization & formulation
Comprehensive analytical services
for biopharmaceuticals
36
Genetic and pharmac
ological approach
Biomarker
expression
Post translational
modifications
Cellular processes
Assay development
and screening
Translational research
QC & stability testing
TARGET ID
TARGET
VALIDATION
HIT ID HIT TO LEAD LEAD OPTIMISATION
READY
PRODUCTS
PRECLINICAL/CLINICAL
CANDIDATE
SELVITA
TODAY
TO
BE
ACQUIRED
/
DEVELOPED
HTS/ vHTS/ HCS
Macrocyles library
Fragment, ligand and
structure-based drug
design
Biophysical methods
In vitro pharmacology & phenotypic
testing
Early tox
ADME/DMPK
In vivo inflammation & infection
CADD and AI
Protein production and X-ray
Medicinal and synthetic chemistry
Batch release for
clinical trials (GMP)
Ex vivo biomarker
research
GLP Bioanalysis
Solid state
Non-GLP tox
Comprehensive offer of drug discovery & drug development services

Specializing in prime research solutions and focus on the
translational offer
Further development of
Inflammation, Respiratory,
Infection
Strenghtening Oncology/
Immunooncology
Expanding Neuroscience
• Developing in vivo offer
(initially by partnering then in house)
• Platform of profiled primary
human tumour cells & tumor
organoids
• HCS models, tailor made PDXs
• Building on existing neuro-inflammation
assays & models
• Partnering and/or acquisition of more
specialised in vivo models
• Establishment of tissue biobank
from in vivo animal models
• Developing new assays with more
complex read outs
• Addressing the challenges related to
post-Covid lung injury syndrom
37

Focus on therapeutic
areas and problem-
solving approach
Integrate Drug
Discovery departments
through projects
Integrated Drug Discovery Approach
HELP CLIENTS TO DISCOVER NEW DRUGS
by offering full package including AI solutions
38
• focus on the protein properties by utilisation of modern structural biology methodologies
• HIT ID by library screening and fragment-based drug discovery (FBDD) approach
• optimize leads by early introduction of translational strategies for compound de-risking
Increase visibility
with high-end Drug
Discovery partnerships
Bringing larger revenue
streams with increased
stability

0.8
3.0
2021 2026
30%
CAGR
AI influence on the drug discovery process:
• Improving effectiveness of ongoing projects and opening
new options especially for rare diseases
• Process could be faster and cheaper = possibility for
more new drugs
Forecasted dynamic growth of AI services in drug discovery
processes, CAGR >30%
Introduction of AI services in Drug Discovery process
Dynamic growth of global AI in Drug Discovery (USDbn)
Source: https://www.globenewswire.com/news-release/2022/01/18/2368751/0/en/Pharma-
Industry-Players-Leverage-AI-For-Drug-Discovery-By-Using-Precise-Molecular-Target-
Identification-As-Per-The-Business-Research-Company-s-Artificial-Intelligence-AI-In-Drug-Di.html
39
Our objective: To make all relevant drug discovery and
development services supported by AI tools by 2025
based on extensive Selvita drug discovery expertise and AI
excellence of Ardigen team in a new model of cooperation
• Selvita covering in-house basic/general AI/ML
services
• Ardigen delivering advanced services and
focus/specialized tools

Regulatory services market
• By 2028 market for outsourcing analytical services will
accelerate at a CAGR of 8-9%, reaching USD 2.5 billion in
Europe and 5.4 billion in the US
• The market is fragmented with dozen players occupying
the market share, creating exciting opportunities for
companies like Selvita offering CRO and CDMO services
• Approx. 36% of the growth originates from the US alone
Source: Pharmaceutical Analytical Testing Outsourcing Market Report, 2028 (grandviewresearch.com)

41
Regulatory services
the seed of the Drug Development segment
Action Plan
• Creating a comprehensive platform for testing small and large molecules throughout the
CMC cycle and batch release testing
• Selvita’s capabilities should comprise capabilities from IND through NDA to the marketed phase
• Drug Development Department is a natural and logical extension of drug discovery capabilities
Required Steps
• Partnering or acquisition of CDMO to create a comprehensive portfolio of services (GMP production,
development of formulation, and analytical testing starting)
• Investments in the analytical platform for biopharmaceutical testing to ensure Selvita
can support Clients in earlier stages of drug development
• Increasing capacity for testing small molecules and bioanalytical testing
Transforming Regulatory department into a fully-fledged drug development segment

42
Ardigen - in the perspective of 2025, the company is
planned to become more independent
Ardigen is a rapidly growing company with an attractive offer of AI services. It operates
in a market that is expanding exponentially. The strategy for further development will
be based on:
• Scaling the Digital CRO segment - maintaining high margins and gradually shifting
the business towards larger contracts, long-term cooperation
• Further development of AI platforms - after the first commercial validations, each
platform requires a dedicated strategy of further development to achieve
commercialization at a satisfactory level, which will ensure even higher margins
than currently provided services
• Systematic strengthening of the presence on the American market (currently the
Company has a sales team of three)
By 2025, Ardigen will become more independent from Selvita

Factors driving the
organic growth

44
Experienced scientific team:
potential for further growth
Strengthening Selvita’s employer brand
• Presence in attractive science centers: Krakow, Zagreb, Cambridge,
Boston
• Higher level of life science education in Poland - new specializations
• Attractive market for employees in PL, CRO - decreasing distance to
the countries of Western Europe
• Over 6.000 applications for research positions in 2021
A stable research team with great potential for further development
• An extensive employee stock ownership program significantly
improves employee retention
• Relatively young team
Maximizing the use of the new, post-covid model of partially remote
work will attract people who do not want to move to PL / CRO
The team's growing experience is a potential
for further growth of the revenue per employee
~20% scientists at
Selvita laboratories
in Poland are
foreigners
44% of scientists
with a Ph.D. title
24 nationalities

45
Research space – a key factor for further development
Along with the development of the biotechnology sector, the laboratory
space available for rent was saturated
For medium and large companies, building their own laboratories is the
optimal solution
• Cost-effective - specialized space is more expensive to rent
• Independence / security
The construction of the first stage of Selvita Research Center in Krakow
is underway
• Launch planned for Q1 2023
• Possibility to create approx. 250 new jobs for scientists
By 2025, execution of the second stage of expansion is planned
In Q1 2022, the second plot of land in Krakow was purchased
• Doubling the development opportunities
• Ultimately, the possibility of completing four stages & 1,000 additional jobs
45

46
Organic growth supported by additional lab space
Estimated number of employees and lab space (m2) (organic growth)
• Estimated organic CAGR growth of 23% translates into approx. 14% increase in head count y/y
• Estimated cash needs for the completion of the 1st stage and construction of the 2nd stage are ~60m EUR.
Financed by own funds, bank loans and grants (1st stage)
• The completion date of the 2nd stage will be tailored to Selvita’s needs, Q1-Q3 2025
• The development in Zagreb and Poznan is planned based on the leased space
1st stage of Selvita
Research Center
2nd stage of Selvita
Research Center
New lab space in KRK
and ZAG
Additional lab space
in ZAG/POZ
No
of
employees
Lab
space
m
2
650
770
880
980
1 100
0
5 000
10 000
15 000
20 000
25 000
30 000
35 000
0
200
400
600
800
1 000
1 200
2021 2022 2023 2024 2025
No. of employees (average per year) Lab space

47
Financing the Strategy 2022-2025
• The capital expenditures will be financed with own funds, grants, as well as with bank loans and debt
instruments, including leasing agreements. The assumed target level of net debt to EBITDA is below 3x
• Acquisitions will be financed with own funds and debt. The Company will consider possible stock swaps or
follow-up issuance only in the case of significant transactions
40
60
110
Organic growth Laboratory space* Acquisitions
EUR
210m
88
115
7
Generated cash Bank loans/Leasings Grants
EUR
210
* Includes the phase I & II of Selvita Research Centre construction

49
Strategic goals for 2022-2025
Selvita as a leading global preclinical CRO providing services
in the field of drug discovery and development, accelerating access to
new therapies for patients
Organic growth + growth through acquisitions
Focus on services with high customer value
• Specialization in selected therapeutic areas
• Unique competences
Strong presence in the largest markets in the US and UK
Comprehensive offer in the area of drug discovery and development
• Supplementing the drug discovery offer
• Building the drug development segment

/company/selvita/ SelvitaKrakow
/SelvitaGroup
Contact us: ir@selvita.com

Glossary
• AI - Artificial Intelligence
• ADME - Absorption. Distribution Metabolism Excretion
• API - Active Pharmaceuticsl Ingredient
• CADD - Computer Assisted Drug Discovery
• CDMO - Contract Development and Manufacturing
Organization
• CLO - Contract Laboratory Organization
• CMC - Chemistry, Manufacturing and Controls
• CNS - Central Nervous System
• CRO - Contract Reserach Organization
• DD - Drug Discovery
• DMPK - Drug Metabolism and Pharmacokinetics
• FBDD - Fragment- Based Drug Discovery
• GLP - Good Laboratory Practice
• GMP - Good Manufacturing Practice
• HCS - High Content Screening
• HTS - High Throughput Screening
• IDD - Integrated Drug Discovery
• IND - Investigational New Drug
• ML - Machine Learning
• NDA - New Drug Application
• PDX - Patient Derived Xenograft
• R&D - Research and Development
• TA - Therapeutic Area
• QC - Quality Control

Selvita_Development-Strategy-2022-2025.pdf

More Related Content

Similar to Selvita_Development-Strategy-2022-2025.pdf (20)

Recently uploaded (20)

Selvita_Development-Strategy-2022-2025.pdf